Self-Powered α Radionuclide Nanomedicine: Mitochondria-Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy.

IF 27.4 1区材料科学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Advanced Materials Pub Date : 2025-07-02 DOI:10.1002/adma.202504612

Xian Li,Chaochao Wang,Yelin Wu,Jiajia Zhang,Han Zhang,Shanshan Qin,Linglin Tang,Fei Yu

{"title":"Self-Powered α Radionuclide Nanomedicine: Mitochondria-Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy.","authors":"Xian Li,Chaochao Wang,Yelin Wu,Jiajia Zhang,Han Zhang,Shanshan Qin,Linglin Tang,Fei Yu","doi":"10.1002/adma.202504612","DOIUrl":null,"url":null,"abstract":"Internal Radionuclide Therapy (IRT) faces significant challenges, particularly the limited controlled penetration depth of conventional β rays and the inefficient targeted delivery of α-emitters. In this study, a mitochondria-targeted, self-powered α radionuclide nanomedicine, and pioneer a groundbreaking \"suborganelle precise radiodynamic immunotherapy\" paradigm that synergistically integrates physical irradiation, catalytic chemistry, and immunomodulation to overcome the historical limitations of IRT is developed. The innovation establishes a \"radionuclide energy internal cycling\" strategy through 223RaCl2 (the first FDA-approved α-emitter), unlocking three synergistic therapies from one radionuclide: precise ionizing radiation, self-powered catalysis, and immunogenic reprogramming. This paradigm uniquely exploits the full decay spectrum (α particles, β electrons, γ photons) to synchronize physical, chemical, and biological anti-tumor mechanisms without requiring external energy inputs, offering a transformative solution to overcome the physical-biological barriers of IRT and bridge localized eradication with systemic immune regulation.","PeriodicalId":114,"journal":{"name":"Advanced Materials","volume":"104 1","pages":"e2504612"},"PeriodicalIF":27.4000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Materials","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1002/adma.202504612","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Internal Radionuclide Therapy (IRT) faces significant challenges, particularly the limited controlled penetration depth of conventional β rays and the inefficient targeted delivery of α-emitters. In this study, a mitochondria-targeted, self-powered α radionuclide nanomedicine, and pioneer a groundbreaking "suborganelle precise radiodynamic immunotherapy" paradigm that synergistically integrates physical irradiation, catalytic chemistry, and immunomodulation to overcome the historical limitations of IRT is developed. The innovation establishes a "radionuclide energy internal cycling" strategy through 223RaCl2 (the first FDA-approved α-emitter), unlocking three synergistic therapies from one radionuclide: precise ionizing radiation, self-powered catalysis, and immunogenic reprogramming. This paradigm uniquely exploits the full decay spectrum (α particles, β electrons, γ photons) to synchronize physical, chemical, and biological anti-tumor mechanisms without requiring external energy inputs, offering a transformative solution to overcome the physical-biological barriers of IRT and bridge localized eradication with systemic immune regulation.

查看原文本刊更多论文

自供电α放射性核素纳米医学：线粒体靶向多模态能量循环用于放大放射免疫治疗。

内部放射性核素治疗（IRT）面临着重大挑战，特别是传统β射线的可控制穿透深度有限，α-发射器的靶向递送效率低下。本研究开发了一种线粒体靶向、自供电的α放射性核素纳米药物，并开创了一种开创性的“亚细胞器精确放射动力学免疫治疗”范式，该范式协同整合了物理照射、催化化学和免疫调节，以克服IRT的历史局限性。该创新通过223RaCl2 （fda批准的首个α-发射器）建立了“放射性核素能量内部循环”策略，释放了一种放射性核素的三种协同疗法：精确电离辐射、自供电催化和免疫原性重编程。这种模式独特地利用了全衰变谱（α粒子、β电子、γ光子）来同步物理、化学和生物抗肿瘤机制，而不需要外部能量输入，提供了一种变革性的解决方案，以克服IRT的物理-生物障碍，并将局部根除与系统免疫调节联系起来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advanced Materials 工程技术-材料科学：综合

CiteScore

43.00

自引率

4.10%

发文量

2182

审稿时长

2 months

期刊介绍： Advanced Materials, one of the world's most prestigious journals and the foundation of the Advanced portfolio, is the home of choice for best-in-class materials science for more than 30 years. Following this fast-growing and interdisciplinary field, we are considering and publishing the most important discoveries on any and all materials from materials scientists, chemists, physicists, engineers as well as health and life scientists and bringing you the latest results and trends in modern materials-related research every week.